Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin degludec/insulin aspart 15
Drug: insulin degludec
Drug: insulin aspart
Drug: placebo

First Posted Date: 2013-01-23

Last Posted Date: 2015-03-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT01773798

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide

First Posted Date: 2013-01-11

Last Posted Date: 2014-06-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01766245

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease
Inflammation

Interventions: Drug: placebo
Drug: NNC0114-0006

First Posted Date: 2012-12-17

Last Posted Date: 2017-03-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 53

Registration Number: NCT01751152

Locations: 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain

Growth Response in Girls With Turner Syndrome

Phase 4

Completed

Conditions: Genetic Disorder
Turner Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-11-27

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT01734486

Locations: 🇫🇷
Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

Phase 4

Completed

Conditions: Small for Gestational Age
Foetal Growth Problem

Interventions: Drug: somatropin

First Posted Date: 2012-11-27

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 57

Registration Number: NCT01734447

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris, France

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2012-11-22

Last Posted Date: 2020-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT01731600

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Healthy

Interventions: Drug: 148-0287-A-4.2mM-cartridge
Drug: placebo
Drug: sodium chloride 0.9% w/v
Drug: insulin glargine

First Posted Date: 2012-11-21

Last Posted Date: 2013-07-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01730014

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: metformin

First Posted Date: 2012-11-02

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 150

Registration Number: NCT01720290

Locations: 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin
Drug: repaglinide
Drug: isophane human insulin

First Posted Date: 2012-11-02

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 159

Registration Number: NCT01720303

Locations: 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2012-11-02

Last Posted Date: 2019-06-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3297

Registration Number: NCT01720446

Locations: 🇬🇧
Novo Nordisk Investigational Site, Torquay, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy